- Investing Ideas
- /
- Household Healthcare Sector
Household Healthcare Sector
Results
2306
All the companies in the healthcare sector, including healthcare provider and equipment, healthcare tech, pharmaceuticals, biotech and life sciences.
2306 companies
Surgery Partners
Market Cap: US$2.9b
Owns and operates a network of surgical facilities and ancillary services in the United States.
SGRY
US$22.60
7D
-4.4%
1Y
-7.5%
Envista Holdings
Market Cap: US$2.8b
Develops, manufactures, markets, and sells dental products in the United States, China, and internationally.
NVST
US$16.87
7D
-6.7%
1Y
-6.1%
Crinetics Pharmaceuticals
Market Cap: US$2.8b
A clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
CRNX
US$30.11
7D
-3.5%
1Y
-38.1%
Concentra Group Holdings Parent
Market Cap: US$2.8b
Provides occupational health services in the United States.
CON
US$21.41
7D
-6.2%
1Y
n/a
Hinge Health
Market Cap: US$2.5b
Develops health care software for joint and muscle health.
HNGE
US$37.56
7D
n/a
1Y
n/a
Immunovant
Market Cap: US$2.4b
A clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases.
IMVT
US$14.56
7D
4.6%
1Y
-48.7%
MoonLake Immunotherapeutics
Market Cap: US$2.4b
A clinical stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases.
MLTX
US$38.51
7D
2.3%
1Y
-3.6%
HUTCHMED (China)
Market Cap: UK£1.8b
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally.
HCM
UK£2.09
7D
3.1%
1Y
-31.3%
Xenon Pharmaceuticals
Market Cap: US$2.4b
A neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada.
XENE
US$30.46
7D
2.4%
1Y
-21.5%
LivaNova
Market Cap: US$2.4b
A medical technology company, designs, develops, manufactures, markets, and sells products and therapies for neurological and cardiac conditions worldwide.
LIVN
US$43.18
7D
-1.5%
1Y
-27.3%
Apogee Therapeutics
Market Cap: US$2.4b
A clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other inflammatory and immunology indications.
APGE
US$40.18
7D
0.8%
1Y
-16.1%
ImmunityBio
Market Cap: US$2.3b
A commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases.
IBRX
US$2.68
7D
0.4%
1Y
-59.9%
Amneal Pharmaceuticals
Market Cap: US$2.3b
A global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.
AMRX
US$7.19
7D
-4.1%
1Y
11.6%
Veracyte
Market Cap: US$2.3b
Operates as a diagnostics company in the United States and internationally.
VCYT
US$27.61
7D
-3.1%
1Y
27.7%
Mirum Pharmaceuticals
Market Cap: US$2.2b
A biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.
MIRM
US$44.31
7D
-0.2%
1Y
69.0%
LifeStance Health Group
Market Cap: US$2.2b
Through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States.
LFST
US$5.62
7D
-2.9%
1Y
-3.1%
Organon
Market Cap: US$2.2b
Develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally.
OGN
US$8.69
7D
-0.9%
1Y
-59.3%
Vericel
Market Cap: US$2.2b
A commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America.
VCEL
US$41.07
7D
-2.9%
1Y
-18.4%
Apellis Pharmaceuticals
Market Cap: US$2.2b
A commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs.
APLS
US$17.78
7D
8.7%
1Y
-55.2%
NewAmsterdam Pharma
Market Cap: US$2.2b
A late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease.
NAMS
US$18.51
7D
-1.3%
1Y
-5.5%
Belite Bio
Market Cap: US$2.2b
A clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States.
BLTE
US$64.63
7D
-3.6%
1Y
41.8%
Acadia Healthcare Company
Market Cap: US$2.2b
Provides behavioral healthcare services in the United States and Puerto Rico.
ACHC
US$22.96
7D
-10.5%
1Y
-64.3%
Ardent Health Partners
Market Cap: US$2.1b
Owns and operates a network of hospitals and clinics that provides a range of healthcare services in the United States.
ARDT
US$14.80
7D
-2.8%
1Y
n/a
Arrowhead Pharmaceuticals
Market Cap: US$2.1b
Develops medicines for the treatment of intractable diseases in the United States.
ARWR
US$15.39
7D
0.3%
1Y
-37.6%
BioCryst Pharmaceuticals
Market Cap: US$2.1b
A biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases.
BCRX
US$10.39
7D
1.8%
1Y
64.1%
Kymera Therapeutics
Market Cap: US$2.0b
A clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system.
KYMR
US$30.13
7D
1.3%
1Y
-15.6%
Harmony Biosciences Holdings
Market Cap: US$2.0b
A commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States.
HRMY
US$34.50
7D
3.3%
1Y
14.3%
Amicus Therapeutics
Market Cap: US$2.0b
A biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally.
FOLD
US$6.34
7D
7.8%
1Y
-34.8%
Ligand Pharmaceuticals
Market Cap: US$2.0b
A biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide.
LGND
US$102.45
7D
-2.5%
1Y
17.4%
QuidelOrtho
Market Cap: US$2.0b
Provides diagnostic testing solutions.
QDEL
US$30.18
7D
-8.6%
1Y
-27.9%
Addus HomeCare
Market Cap: US$2.0b
Provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States.
ADUS
US$111.53
7D
1.5%
1Y
2.3%
CG Oncology
Market Cap: US$2.0b
A late-stage clinical biopharmaceutical company, develops and commercializes backbone bladder-sparing therapeutics for patients with bladder cancer.
CGON
US$25.76
7D
1.6%
1Y
-14.1%
Denali Therapeutics
Market Cap: US$2.0b
A biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases.
DNLI
US$13.66
7D
-3.5%
1Y
-29.1%
NovoCure
Market Cap: US$2.0b
An oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally.
NVCR
US$18.11
7D
3.0%
1Y
-18.8%
GeneDx Holdings
Market Cap: US$1.9b
A genomics company, provides genetic testing services.
WGS
US$67.33
7D
5.8%
1Y
241.4%
Kiniksa Pharmaceuticals International
Market Cap: US$1.9b
A biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide.
KNSA
US$25.95
7D
0.3%
1Y
35.4%